CTOs on the Move

Buoy Health

www.buoyhealth.com

 
Buoy is a Boston-based digital health company that uses AI technology to provide personalized clinical support the moment an individual has a health concern. Developed out of the Harvard Innovation Labs by a team of doctors and data scientists, Buoy navigates people through the healthcare system intelligently, delivering triage at scale, and connecting them with the right care endpoints at the right time based on self-reported symptoms.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Jeffrey Lui
Chief Technology Officer Profile
Corey McCosh
Director Information Security Profile

Funding

Buoy Health raised $15M on 08/15/2019
Buoy Health raised $37.5M on 11/10/2020

Similar Companies

Oakland Community Health Network

OCHN has a long-standing history of promoting independence, choice, and community inclusion for adults and children with intellectual / developmental disabilities, mental health concerns, and substance use disorders. Its mission to “inspire hope, empower people, and strengthen communities” reflects an unyielding belief in a "Valuable System for Valued People." Programs and supports provided by OCHN`s service network are available at www.oaklandchn.org. Most people who receive services through Oakland County`s public mental health system, which is managed by OCHN, have Medicaid insurance coverage.

Eniva Corporation

Eniva Corporation is a Anoka, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Care Medical Technologies

Health Care Medical Technologies, Inc. is a Sioux Falls, SD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northwestern University Clinical andTranslational Sciences Institute (NUCATS)

NUCATS provides scientists with consultative resources and expertise in order to accelerate how quickly transformative scientific discoveries make their way to patients and the community. It is our goal to continually increase the quality, safety, efficiency and speed of innovative clinical and translational research.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.